Monte Rosa Therapeutics, Inc. SEC filings GLUE
Monte Rosa Therapeutics, Inc. has 401 filings in SEC EDGAR's recent list, going back to Sep 29, 2020. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 1, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 8, 2026 | Sep 8, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 11, 2026 | Jun 11, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 7, 2026 | May 7, 2026 |
| ARS | Annual report to shareholders | Apr 29, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 29, 2026 | — |
| DEF 14A | Proxy statement | Apr 29, 2026 | Apr 29, 2026 |
| S-8 | Employee stock plan registration | Mar 17, 2026 | — |
| 10-K | Annual report | Mar 17, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 17, 2026 | Mar 17, 2026 |
| S-3ASR | Automatic shelf registration | Feb 11, 2026 | — |
| 8-K |
Current report
Officer or director change
|
Feb 10, 2026 | Feb 9, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Jan 9, 2026 | Jan 8, 2026 |
| 424B5 | Prospectus supplement | Jan 9, 2026 | — |
| 8-K |
Current report
Other events
|
Jan 7, 2026 | Jan 7, 2026 |
| 424B5 | Prospectus supplement | Jan 7, 2026 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jan 7, 2026 | Jan 7, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 16, 2025 | Dec 16, 2025 |
| 10-Q | Quarterly report | Nov 6, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 6, 2025 | Nov 6, 2025 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Sep 15, 2025 | Sep 15, 2025 |
| UPLOAD | Letter from the SEC | Aug 21, 2025 | — |
| 10-Q | Quarterly report | Aug 7, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 7, 2025 | Aug 7, 2025 |
| CORRESP | Letter to the SEC | Jul 22, 2025 | — |
| UPLOAD | Letter from the SEC | Jul 15, 2025 | — |
| 8-K |
Current report
Shareholder vote results
|
Jun 13, 2025 | Jun 13, 2025 |
| 10-Q | Quarterly report | May 8, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 8, 2025 | May 8, 2025 |
| ARS | Annual report to shareholders | Apr 25, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 25, 2025 | — |
| DEF 14A | Proxy statement | Apr 25, 2025 | Apr 25, 2025 |
| EFFECT | Filing | Mar 31, 2025 | — |
| CORRESP | Letter to the SEC | Mar 27, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 26, 2025 | — |
| S-3 | Shelf registration | Mar 20, 2025 | — |
| S-8 | Employee stock plan registration | Mar 20, 2025 | — |
| 10-K | Annual report | Mar 20, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 20, 2025 | Mar 20, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Jan 10, 2025 | Jan 10, 2025 |
| 8-K |
Current report
Officer or director change
|
Dec 13, 2024 | Dec 11, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 5, 2024 | Dec 5, 2024 |
| 10-Q | Quarterly report | Nov 7, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 7, 2024 | Nov 7, 2024 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Oct 28, 2024 | Oct 25, 2024 |
| 10-Q | Quarterly report | Aug 8, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 8, 2024 | Aug 8, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 27, 2024 | Jun 27, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 12, 2024 | Jun 12, 2024 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
May 30, 2024 | May 28, 2024 |
| 8-K |
Current report
Material agreement
|
May 16, 2024 | May 15, 2024 |
| 424B5 | Prospectus supplement | May 16, 2024 | — |
| 424B5 | Prospectus supplement | May 15, 2024 | — |
| 10-Q | Quarterly report | May 9, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 9, 2024 | May 9, 2024 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
May 2, 2024 | Apr 29, 2024 |
| ARS | Annual report to shareholders | Apr 26, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | Apr 26, 2024 | — |
| DEF 14A | Proxy statement | Apr 26, 2024 | Apr 26, 2024 |
| S-8 | Employee stock plan registration | Mar 14, 2024 | — |
| 10-K | Annual report | Mar 14, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 14, 2024 | Mar 14, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 8, 2024 | Jan 8, 2024 |
| 10-Q | Quarterly report | Nov 9, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2023 | Nov 9, 2023 |
| 8-K |
Current report
Material agreement, Other events
|
Oct 26, 2023 | Oct 26, 2023 |
| 424B5 | Prospectus supplement | Oct 26, 2023 | — |
| 8-K |
Current report
Material agreement, Regulation FD disclosure, Other events
|
Oct 17, 2023 | Oct 16, 2023 |
| 10-Q | Quarterly report | Aug 10, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2023 | Aug 10, 2023 |
| 8-K |
Current report
Officer or director change
|
Jul 26, 2023 | Jul 26, 2023 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Jun 14, 2023 | Jun 14, 2023 |
| 10-Q | Quarterly report | May 11, 2023 | Mar 31, 2023 |
| 8-K |
Current report
Results of operations
|
May 11, 2023 | May 11, 2023 |
| ARS | Annual report to shareholders | Apr 26, 2023 | Dec 31, 2022 |
| DEFA14A | Additional proxy material | Apr 26, 2023 | — |
| DEF 14A | Proxy statement | Apr 26, 2023 | Apr 26, 2023 |
| PRE 14A | Preliminary proxy statement | Apr 12, 2023 | Apr 12, 2023 |
| 8-K |
Current report
Officer or director change
|
Mar 23, 2023 | Mar 22, 2023 |
| S-8 | Employee stock plan registration | Mar 16, 2023 | — |
| 10-K | Annual report | Mar 16, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 16, 2023 | Mar 16, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 9, 2023 | Jan 9, 2023 |
| 10-Q | Quarterly report | Nov 10, 2022 | Sep 30, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 10, 2022 | Nov 10, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 24, 2022 | Oct 24, 2022 |
| 10-Q | Quarterly report | Aug 11, 2022 | Jun 30, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2022 | Aug 11, 2022 |
| EFFECT | Filing | Jul 13, 2022 | — |
| CORRESP | Letter to the SEC | Jul 11, 2022 | — |
| UPLOAD | Letter from the SEC | Jul 8, 2022 | — |
| S-3 | Shelf registration | Jul 1, 2022 | — |
| 8-K |
Current report
Shareholder vote results
|
Jun 15, 2022 | Jun 15, 2022 |
| DEFA14A | Additional proxy material | Jun 8, 2022 | — |
| 10-Q | Quarterly report | May 11, 2022 | Mar 31, 2022 |
| 8-K |
Current report
Results of operations
|
May 11, 2022 | May 11, 2022 |
| DEFA14A | Additional proxy material | Apr 28, 2022 | — |
| DEF 14A | Proxy statement | Apr 27, 2022 | Apr 27, 2022 |
| S-8 | Employee stock plan registration | Mar 29, 2022 | — |
| 10-K | Annual report | Mar 29, 2022 | Dec 31, 2021 |
| 8-K |
Current report
Results of operations
|
Mar 29, 2022 | Mar 29, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 10, 2022 | Jan 10, 2022 |
| 8-K |
Current report
Material agreement, New debt
|
Dec 15, 2021 | Dec 14, 2021 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2021 | Nov 10, 2021 |
| 10-Q | Quarterly report | Nov 10, 2021 | Sep 30, 2021 |
| 10-Q | Quarterly report | Aug 12, 2021 | Jun 30, 2021 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2021 | Aug 12, 2021 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Jun 28, 2021 | Jun 28, 2021 |
| S-8 | Employee stock plan registration | Jun 25, 2021 | — |
| 424B4 | Prospectus | Jun 25, 2021 | — |
| SEC STAFF LETTER | Filing | Jun 23, 2021 | — |
| EFFECT | Filing | Jun 23, 2021 | — |
| S-1MEF | Filing | Jun 23, 2021 | — |
| CERT | Filing | Jun 22, 2021 | — |
| 8-A12B | Filing | Jun 21, 2021 | — |
| CORRESP | Letter to the SEC | Jun 21, 2021 | — |
| CORRESP | Letter to the SEC | Jun 21, 2021 | — |
| CORRESP | Letter to the SEC | Jun 21, 2021 | — |
| S-1/A | Amended registration statement | Jun 21, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 15, 2021 | — |
| CORRESP | Letter to the SEC | Jun 11, 2021 | — |
| CORRESP | Letter to the SEC | Jun 9, 2021 | — |
| S-1/A | Amended registration statement | Jun 9, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 7, 2021 | — |
| S-1 | Registration statement | Jun 4, 2021 | — |
| SEC STAFF LETTER | Filing | May 25, 2021 | — |
| DRSLTR | Filing | May 21, 2021 | — |
| DRS/A | Filing | May 21, 2021 | — |
| UPLOAD | Letter from the SEC | May 17, 2021 | — |
| DRS/A | Filing | Apr 30, 2021 | — |
| DRS | Filing | Apr 19, 2021 | — |
| D | Filing | Mar 24, 2021 | — |
| D | Filing | Sep 29, 2020 | — |
Showing 138 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- GLUE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1826457
- Former names
- Monte Rosa Therapeutics, Inc. (until Nov 5, 2026)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.